EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

M I Carlo, B Manley, S Patil, K M Woo, D T Coskey, A Redzematovic, M Arcila, M Ladanyi, W Lee, Y B Chen, C H Lee, D R Feldman und 4 weitere

Kidney Cancer · 2017

DOI: 10.3233/kca-160003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney Cancer, 2017. Verfasst von M I Carlo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutations in VHL, PBRM1, SETD2, BAP1, and KDM5C are common in clear cell renal cell carcinoma (ccRCC), and presence of certain mutations has been associated with outcomes in patients with non-metastatic disease. Limited information is available regarding the correlation between genomic alterations and outcomes in patients with metastatic disease, including response to VEGF-targeted therapy.

Objective

To explore correlations between mutational profiles and cancer-specific outcomes, including response to standard VEGF-targeted agents, in patients with metastatic cc RCC.

Methods

A retrospective review of 105 patients with metastatic ccRCC who had received systemic therapy and had targeted next-generation sequencing of tumors was conducted. Genomic alterations were correlated to outcomes, including overall survival and time to treatment failure to VEGF-targeted therapy.

Results

The most frequent mutations were detected in VHL (83%), PBRM1 (51%), SETD2 (35%), BAP1 (24%), KDM5C (16%), and TERT (14%). Time to treatment failure with VEGF-targeted therapy differed significantly by PBRM1 mutation status ( p = 0.01, median 12.0 months for MT versus 6.9 months for WT) and BAP1 mutation status ( p = 0.01, median 6.4 months for MT versus 11.0 months for WT). Shorter overall survival was associated with TERT mutations ( p = 0.03, median 29.6 months for MT versus 52.6 months for WT) or BAP1 mutations ( p = 0.02, median 28.7 months for MT versus not reached for WT).

Conclusions

Genomic alterations in ccRCC tumors have prognostic implications in patients with metastatic disease. BAP1 and TERT promoter mutations may be present in higher frequency than previously thought, and based on this data, deserve further study for their association with poor prognosis.

Schlagwörter

Stichwörter der Autor:innen

Clear cell renal cell carcinomaVEGF-targeted therapygenomicsprognosis

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Epidemiology/Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Carlo, M. I., Manley, B., Patil, S., Woo, K. M., Coskey, D. T., Redzematovic, A., Arcila, M., Ladanyi, M., Lee, W., Chen, Y. B., Lee, C. H., Feldman, D. R., Hakimi, A. A., Motzer, R. J., Hsieh, J. J., & Voss, M. H. (2017). Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. https://doi.org/10.3233/kca-160003

Vancouver

Carlo MI, Manley B, Patil S, Woo KM, Coskey DT, Redzematovic A, et al. Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer. 2017. doi:10.3233/kca-160003

BibTeX
@article{Carlo2017,
  author = {Carlo, M I and Manley, B and Patil, S and Woo, K M and Coskey, D T and Redzematovic, A and Arcila, M and Ladanyi, M and Lee, W and Chen, Y B and Lee, C H and Feldman, D R and Hakimi, A A and Motzer, R J and Hsieh, J J and Voss, M H},
  title = {Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma},
  journal = {Kidney Cancer},
  year = {2017},
  doi = {10.3233/kca-160003}
}
Kostenlos starten →